SAT0152 A Randomised, Double-Blind, Phase III Study Comparing SB2, An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

Abstract

BackgroundSB2 is developed as a biosimilar of the infliximab reference product (INF).ObjectivesThis is a phase III equivalence study to compare the efficacy, safety, immunogenicity and pharmacokinetics (PK) of SB2 to...